눈주위 트리암시롤론 주사를 이용한 갑상선 안병증의 치료효과
Therapeutic Effects of Periocular Injection of Triamcinolon Acetonide in Patients with Thyroid-Associated Ophthalmopathy
3
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Purpose: The present study investigated the therapeutic effects of periocular triamcinolone acetonide injections to treat inflammatory signs in patients with severe acute thyroid-associated ophthalmopathy. Methods: Twenty-two patients with symptoms of severe acute thyroid ophthalmopathy were enrolled in the present study. The patients received four doses of 20 mg of triamcinolone acetonide via periocular injection into the inferotemporal orbital quadrant every 2 weeks. The changes in visual acuity, intraocular pressure, eye ball motility, exophthalmos, thickness of extraocular muscles, clinical activity score and NOSPECS score were measured. Results: Eighteen of 22 patients (81.8%) showed improvement in soft tissue swelling, ten patients (45.5%) showed improvement in conjunctival hyperemia and one patient showed improvement of ocular motility. Clinical activity score and NOSPECS score had significant improvements. No patient had changes in visual acuity, intraocular pressure, diplopia,proptosis or thickness of extraocular muscles. An ocular adverse effect was found in one patient, who had subcutaneous fat atrophy at the injection site. Conclusions: In patients with severe acute thyroid ophthalmopathy, periocular triamcinolone acetonide injection can be effective to improve acute inflammatory symptoms, without significant adverse effects.
Abstract
Purpose: The present study investigated the therapeutic effects of periocular triamcinolone acetonide injections to treat inflammatory signs in patients with severe acute thyroid-associated ophthalmopathy. Methods: Twenty-two patients with symptoms of severe acute thyroid ophthalmopathy were enrolled in the present study. The patients received four doses of 20 mg of triamcinolone acetonide via periocular injection into the inferotemporal orbital quadrant every 2 weeks. The changes in visual acuity, intraocular pressure, eye ball motility, exophthalmos, thickness of extraocular muscles, clinical activity score and NOSPECS score were measured. Results: Eighteen of 22 patients (81.8%) showed improvement in soft tissue swelling, ten patients (45.5%) showed improvement in conjunctival hyperemia and one patient showed improvement of ocular motility. Clinical activity score and NOSPECS score had significant improvements. No patient had changes in visual acuity, intraocular pressure, diplopia,proptosis or thickness of extraocular muscles. An ocular adverse effect was found in one patient, who had subcutaneous fat atrophy at the injection site. Conclusions: In patients with severe acute thyroid ophthalmopathy, periocular triamcinolone acetonide injection can be effective to improve acute inflammatory symptoms, without significant adverse effects.
참고문헌 (20)
- Garrity JA, "Pathogenesis of graves ophthalmopathy im plications for prediction, prevention, and treatment", Am J Ophthalmol, 142, pp.147~153 (2006)
- Bahn RS, "Choice of therapy and criteria for assessing treatment outcome in thyroid associated ophthalmopathy", Endocrinol Metab Clin North Am, 16, pp.391~407 (1987)
- Bordaberry M, "Repeated peribulbar injections of triamcinolone acetonide a successful and safe treatment for moderate to severe Graves' ophthalmopathy", Acta Ophthalmol, 87, pp.58~64 (2009)
- Ebner R, "Treatment of thyroid associated ophthalmopathy with periocular injections of triamcinolone", Br J Ophthalmol, 88, pp.1380~1386 (2004)
- Poonyathalang A, "Retrobulbar injection of triamcinolone in thyroid associated orbitopathy", J Med Assoc Thai, 88, pp.345~349 (2005)
- 정보영, "갑상선 안병증에서 눈주위 트리암시놀론 주사의 효과", 대한안과학회지, 48(9), pp.1163~1169 (2007), 대한안과학회
- Sergott RC, "Graves ophthalmopathy", Surv Ophthalmol, 26, pp.1~21 (1981)
- Garber MI, "Methylprednisolone in the treatment of exophthalmos", Lancet Lancet, 1, pp.958~960 (1966)
- Werner SC, "Modification of the classification of the eye changes of Graves'disease recommendations of the Ad Hoc Committee of the American Thyroid Association", J Clin Endocrinol Metab, 44, pp.203~204 (1977)
- Mourits MP, "Clinical activity score as a guide in the management of patients with Graves ophthalmopathy", Clin Endocrinol, 47, pp.9~14 (1997)
- 박정민, "안과 초진시 갑상선항진증 환자의 안증상 및 외안근의 변화", 대한안과학회지, 44(10), pp.2~2203 (2003), 대한안과학회
- Hallin ES, "Graves ophthalmopathy I. Simple CT estimates of extraocular muscle volume", Br J Ophthalmol, 72, pp.674~677 (1988)
- Chen YL, "Relationship of eye movement to computed tomographic findings in patients with Graves ophthalmopathy", 72, pp.472~477 (1994)
- Bartalena L, "Treating severe Graves ophthalmopathy", Baillieres Clin Endocrinol Metab, 11, pp.521~536 (1997)
- Koornneef L, "New insights in the human orbital connective tissue", Arch Ophthalmol, 95, pp.1269~1273 (1977)
- Koornneef L, "Orbital septa anatomy and function", Ophthalmology, 86, pp.876~880 (1979)
- O'Connor GR, "Periocular corticosteroid injections uses and abuses", Eye Ear Nose Throat Mon, 55, pp.83~88 (1976)
- Jordan DR, "Coupal D. Orbital mass following injection with depot corticosteroids", Can J Ophthalmol, 36, pp.153~155 (2001)
- Nozik RA, "Orbital rim fat atrophy after repository periocular corticosteroid injection", Am J Ophthalmol, 82, pp.928~930 (1976)
- Droste PJ, "Linear subcutaneous fat atrophy after corticosteroid injection of periocular hemangiomas", Am J Ophthalmol, 105, pp.65~69 (1988)